Hepatic Cirrhosis

Cirrhosis has a compensated phase in which patients may feel well and a decompensated phase defined by onset of complications, including ascites, hepatic encephalopathy, and variceal bleeding. Routine liver enzyme, alkaline phosphatase, and bilirubin values can be normal in cirrhosis; do not use normal results to dismiss concern raised by thrombocytopenia or other clinical evidence of chronic liver disease. ScienceDirectScienceDirectKey Insights and Clinical Pearls in the Identification and Management of Cirrhosis and Its Complications

The immediate clinical task is not simply to label cirrhosis, but to establish the underlying etiology, estimate fibrosis and portal-hypertension burden, and determine whether prior or current decompensation has occurred. Etiologic therapy should be initiated as early as possible at any stage of hepatic disease. ScienceDirectScienceDirectEASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

In metabolic dysfunction-associated steatotic liver disease terminology used in older source materials as NAFLD/NASH, clinical and routine laboratory testing cannot reliably distinguish nonalcoholic fatty liver from steatohepatitis. Liver biopsy with histologic assessment is the reference standard when diagnosis and staging of steatohepatitis or fibrosis are necessary. fdafdaCirculating Biomarkers for Diagnosis of Non-Alcoholic ...

Noninvasive blood- and imaging-based fibrosis tests can support risk stratification, but their predictive performance is context dependent. Patented and nonpatented fibrosis markers predict decompensation largely through association with advanced fibrosis; their prognostic performance declines once cirrhosis is already established. Wolters KluwerWolters KluwerNoninvasive assessment of hepatic decompensation : Hepatology

Enhanced Liver Fibrosis testing has shown prognostic association in mixed liver-disease populations, including an AUC of 0.87 for 6-year prediction of decompensation and liver-related death; however, among patients with established cirrhosis, reported discrimination for liver-related events was lower. Wolters KluwerWolters KluwerNoninvasive assessment of hepatic decompensation : Hepatology Use such tests as adjuncts to—not replacements for—clinical assessment of decompensation and complication risk.

Ascites reflects portal hypertension together with renal sodium and water retention. It is a major landmark in cirrhosis: about 20% of patients with cirrhosis have ascites at first presentation, and about 20% of those presenting with ascites die during the first year after diagnosis. BMJBMJGuidelines on the management of ascites in cirrhosis | Gut

Hyponatremia is categorized as mild at serum sodium 130–135 mmol/L, moderate at 125–129 mmol/L, and severe below 125 mmol/L. BMJBMJGuidelines on the management of ascites in cirrhosis | Gut In a patient with ascites, serial sodium and renal assessment is clinically important because kidney dysfunction, hepatorenal syndrome, and infection are consequential complications of decompensated disease. BMJ+1BMJGuidelines on the management of ascites in cirrhosis | GutScienceDirectEASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

The supplied evidence supports early etiologic treatment across stages of chronic liver disease and emphasizes prompt identification and management of cirrhosis complications. ScienceDirect+1ScienceDirectEASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosisScienceDirectKey Insights and Clinical Pearls in the Identification and Management of Cirrhosis and Its Complications For chronic hepatitis C, direct-acting antiviral treatment prevents progression of HCV-related liver disease and reduces risk of cirrhosis, decompensation, and hepatocellular carcinoma; patients with advanced fibrosis or cirrhosis require linkage to ongoing surveillance for HCV-related complications. IDSAIDSAAASLD/IDSA 2023 Clinical Practice Guidance Update for Testing, Managing, and Treating Hepatitis C Virus Infection

The available sources do not provide sufficient support for a universal U.S. medication regimen, diuretic dosing protocol, paracentesis protocol, variceal prophylaxis regimen, or hepatocellular carcinoma surveillance interval. These decisions should therefore be verified against current disease-specific U.S. guidance and individualized to renal function, sodium concentration, hemodynamics, encephalopathy, infection status, and transplant candidacy.

For suspected cirrhosis, first establish whether the patient is compensated or has experienced ascites, encephalopathy, or variceal bleeding. Concurrently evaluate the cause of liver disease and assess fibrosis using noninvasive tools or biopsy when histology will change management. fda+3fdaCirculating Biomarkers for Diagnosis of Non-Alcoholic ...ScienceDirectEASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosisScienceDirectKey Insights and Clinical Pearls in the Identification and Management of Cirrhosis and Its ComplicationsWolters KluwerNoninvasive assessment of hepatic decompensation : Hepatology

For decompensated disease, identify the active complication and assess for infection, acute kidney injury, hepatorenal syndrome, sodium abnormalities, and hepatocellular carcinoma, all of which can influence the clinical trajectory. BMJ+1BMJGuidelines on the management of ascites in cirrhosis | GutScienceDirectEASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis Refer early to hepatology and involve multidisciplinary teams for complex procedural decisions, including TIPS and abdominal wall hernia repair. BMJBMJGuidelines on the management of ascites in cirrhosis | Gut